CervoMed Inc
CRVO9.330USD
+0.500+5.66%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
81.20MValor de mercado
PerdaP/L TTM
Mais detalhes de CervoMed Inc Empresa
CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. It is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its neflamapimod is in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies and early Alzheimer’s disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke. Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in dementia with Lewy bodies (DLB) and certain other neurological disorders. It is being evaluated in its ongoing RewinD-LB Trial, a Phase 2b study in patients with DLB.
Informações da empresa
Código da empresaCRVO
Nome da EmpresaCervoMed Inc
Data de listagemNov 09, 2016
CEOMr. John J. Alam, M.D.
Número de funcionários15
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 09
Endereço20 Park Plaza, Suite 424
CidadeBOSTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal02116
Telefone16177444400
Sitehttps://cervomed.com/
Código da empresaCRVO
Data de listagemNov 09, 2016
CEOMr. John J. Alam, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Joshua S. Boger, Ph.D.
Dr. Joshua S. Boger, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.06M
--
Mr. John J. Alam, M.D.
Mr. John J. Alam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
730.79K
+0.17%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Independent Director
Independent Director
16.44K
--
Ms. Kelly Blackburn
Ms. Kelly Blackburn
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
13.67K
--
Ms. Jane H. Hollingsworth, M.D.
Ms. Jane H. Hollingsworth, M.D.
Independent Director
Independent Director
899.00
--
Mr. William R. Elder
Mr. William R. Elder
Chief Financial Officer, General Counsel, Corporate Secretary
Chief Financial Officer, General Counsel, Corporate Secretary
--
--
Dr. Marwan Noel Sabbagh, M.D.
Dr. Marwan Noel Sabbagh, M.D.
Independent Director
Independent Director
--
--
Dr. Claudia Ordonez, M.D.
Dr. Claudia Ordonez, M.D.
Senior Vice President - Medical Science
Senior Vice President - Medical Science
--
--
Dr. Marco Verwijs, Ph.D.
Dr. Marco Verwijs, Ph.D.
Executive Vice President - Technical Operations
Executive Vice President - Technical Operations
--
--
Dr. Robert J. Cobuzzi, Jr.
Dr. Robert J. Cobuzzi, Jr.
Director
Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Joshua S. Boger, Ph.D.
Dr. Joshua S. Boger, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.06M
--
Mr. John J. Alam, M.D.
Mr. John J. Alam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
730.79K
+0.17%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Independent Director
Independent Director
16.44K
--
Ms. Kelly Blackburn
Ms. Kelly Blackburn
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
13.67K
--
Ms. Jane H. Hollingsworth, M.D.
Ms. Jane H. Hollingsworth, M.D.
Independent Director
Independent Director
899.00
--
Mr. William R. Elder
Mr. William R. Elder
Chief Financial Officer, General Counsel, Corporate Secretary
Chief Financial Officer, General Counsel, Corporate Secretary
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Boger (Joshua S)
12.15%
AWM Investment Company, Inc.
9.92%
Gregoire (Sylvie L.)
8.40%
Alam (John J)
8.40%
The Vanguard Group, Inc.
4.35%
Other
56.79%
Investidores
Investidores
Proporção
Boger (Joshua S)
12.15%
AWM Investment Company, Inc.
9.92%
Gregoire (Sylvie L.)
8.40%
Alam (John J)
8.40%
The Vanguard Group, Inc.
4.35%
Other
56.79%
Tipos de investidores
Investidores
Proporção
Individual Investor
33.43%
Investment Advisor/Hedge Fund
14.17%
Investment Advisor
10.36%
Research Firm
1.60%
Hedge Fund
0.09%
Bank and Trust
0.06%
Pension Fund
0.02%
Other
40.27%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
117
5.20M
59.72%
-1.49M
2025Q1
117
5.20M
61.51%
-1.51M
2024Q4
109
4.40M
53.34%
-2.51M
2024Q3
92
6.43M
77.88%
-414.79K
2024Q2
78
6.37M
77.13%
+108.27K
2024Q1
52
5.40M
90.18%
+2.52M
2023Q4
54
3.10M
54.81%
+657.18K
2023Q3
54
3.32M
58.71%
+3.16M
2023Q2
46
125.98K
9.26%
-42.41K
2023Q1
54
143.15K
10.53%
-17.76K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Boger (Joshua S)
1.06M
12.15%
--
--
Apr 24, 2025
AWM Investment Company, Inc.
863.20K
9.92%
+863.20K
--
Mar 31, 2025
Gregoire (Sylvie L.)
730.79K
8.4%
-1.25K
-0.17%
Apr 24, 2025
Alam (John J)
730.79K
8.4%
+1.25K
+0.17%
Apr 24, 2025
The Vanguard Group, Inc.
378.66K
4.35%
-4.83K
-1.26%
Mar 31, 2025
Zavrl (Frank E.)
353.01K
4.06%
--
--
Apr 24, 2025
BlackRock Institutional Trust Company, N.A.
321.48K
3.69%
+24.03K
+8.08%
Mar 31, 2025
Morgan Stanley & Co. LLC
130.60K
1.5%
+87.90K
+205.86%
Mar 31, 2025
Geode Capital Management, L.L.C.
116.48K
1.34%
+1.65K
+1.43%
Mar 31, 2025
State Street Global Advisors (US)
112.06K
1.29%
-4.20K
-3.61%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Health Innovation Active ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proporção0.01%
iShares Russell 2000 Growth ETF
Proporção0%
Global X Russell 2000 ETF
Proporção0%
Proshares Ultra Russell 2000
Proporção0%
ProShares UltraPro Russell2000
Proporção0%
iShares Health Innovation Active ETF
Proporção0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporção0%
iShares Russell 2000 ETF
Proporção0%
ProShares Hedge Replication ETF
Proporção0%
Avantis US Small Cap Equity ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Aug 16, 2023
Merger
1.5<1
Aug 16, 2023
Merger
1.5<1
Aug 16, 2023
Merger
1.5<1
Aug 16, 2023
Merger
1.5<1
Apr 18, 2022
Merger
50<1
Apr 18, 2022
Merger
50<1
Data
Tipo
Proporção
Aug 16, 2023
Merger
1.5<1
Aug 16, 2023
Merger
1.5<1
Aug 16, 2023
Merger
1.5<1
Aug 16, 2023
Merger
1.5<1
Apr 18, 2022
Merger
50<1
Apr 18, 2022
Merger
50<1
Apr 18, 2022
Merger
50<1
Apr 18, 2022
Merger
50<1
